-
Subject Areas on Research
-
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
-
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
-
A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion.
-
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
-
A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities.
-
A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.
-
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.
-
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
-
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
-
ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy.
-
Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study.
-
Advanced prostatic carcinoma: pulmonary manifestations.
-
Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience.
-
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
-
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
-
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
-
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.
-
Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.
-
Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma.
-
Busulfan therapy of central nervous system xenografts in athymic mice.
-
Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
-
Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.
-
Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents.
-
Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma.
-
Combination chemotherapy for primary amyloidosis reconsidered.
-
Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma.
-
Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma.
-
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
-
Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
-
Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.
-
Cyclocreatine in cancer chemotherapy.
-
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
-
Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
-
Development of a model of melphalan-induced gastrointestinal toxicity in mice.
-
Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.
-
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
-
Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells.
-
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
-
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
-
Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
-
Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta.
-
Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion.
-
Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
-
Experimental chemotherapy of human medulloblastoma with classical alkylators.
-
FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
-
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
-
Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.
-
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
-
Future directions in regional treatment strategies for melanoma and sarcoma.
-
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.
-
Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line.
-
Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
-
High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
-
High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.
-
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
-
High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.
-
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
-
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
-
High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study.
-
High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
-
High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
-
Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.
-
Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma.
-
Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma.
-
In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
-
Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.
-
International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients.
-
Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats.
-
Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats.
-
Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.
-
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.
-
Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma.
-
Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
-
L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma.
-
Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms.
-
Management of recurrent melanoma of the extremity.
-
Managing the complications of plasma cell myeloma.
-
Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion.
-
Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.
-
Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine.
-
Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
-
Modulation of resistance to regional chemotherapy in the extremity melanoma model.
-
Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report.
-
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
-
Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
-
Neurologic manifestations of essential thrombocythemia.
-
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
-
Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?
-
Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma.
-
Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma.
-
Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI.
-
Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies.
-
Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs with malignant melanoma.
-
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
-
Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development.
-
Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma.
-
Phase II trial of intravenous melphalan in advanced colorectal carcinoma.
-
Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.
-
Predicting disease progression after regional therapy for in-transit melanoma.
-
Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
-
Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.
-
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
-
Re: Toxicity of intrathecal melphalan.
-
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
-
Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma.
-
Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome.
-
Role of glutathione in cellular resistance to alkylating agents.
-
SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
-
Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy.
-
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
-
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
-
Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.
-
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
-
Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
-
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
-
The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft.
-
The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma.
-
The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.
-
The role of hyperthermia in regional alkylating agent chemotherapy.
-
Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR.
-
Unexpected toxicity associated with use of body surface area for dosing melphalan in the dog.
-
Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma.
-
Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium.
-
Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium.
-
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
-
Keywords of People
-
Craciunescu, Oana,
Professor of Radiation Oncology,
Radiation Oncology
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
Weinhold, Kent James,
Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, in the School of Medicine,
Immunology